DIAGO T790M Mutation Detection Kit

EGFR mutation is known as the highest mutation in lung cancer. Most of the point mutations in the EGFR gene are associated with exon 19 deletions, and exon 20 L858R substitutions are up to 80%. Lung cancer patients with EGFR mutations will use first-line Tyrosine Kinase Inhibitors (TKI) to treat these mutations. At the time of drug consumption, the patient showed symptoms of relapse due to drug resistance mechanisms (T790M mutation). In Indonesia, the prevalence of the T790M mutation was reported to be higher, up to 48.7% after consumption of first-line TKI compared to the initial T790M mutation, which was only 5%. A single and non-invasive detection of T790M to monitor the success of first-line TKI treatment is urgently needed. The DIAGO T790M Mutation Detection Kit is an in-vitro diagnostic kit that has the ability to detect T790M mutations in lung cancer patients after first-line TKI treatment. The sample is collected by a non-invasive procedure from the patient's blood (Cell-Free DNA). This kit amplifies the DNA fragment from T790M using a double-labeled probe to provide high sensitivity and specificity. DIAGO T790M Mutation Detection Kit is an open system with a minimum of 2 channels (FAM & CY5) and can be used on various machines that have been widely distributed nationally after the Covid-19 pandemic (PCR Utilization).